These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 8393954)

  • 1. Investigation of the mechanism of hypertension in apparent mineralocorticoid excess.
    Speiser PW; Riddick LM; Martin K; New MI
    Metabolism; 1993 Jul; 42(7):843-5. PubMed ID: 8393954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human hypertension caused by mutations in the 11 beta-hydroxysteroid dehydrogenase gene: a molecular analysis of apparent mineralocorticoid excess.
    Whorwood CB; Stewart PM
    J Hypertens Suppl; 1996 Dec; 14(5):S19-24. PubMed ID: 9120678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Congenital and acquired syndromes of apparent mineralocorticoid excess.
    Edwards CR; Walker BR; Benediktsson R; Seckl JR
    J Steroid Biochem Mol Biol; 1993 Apr; 45(1-3):1-5. PubMed ID: 8386930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apparent mineralocorticoid excess syndromes.
    Shimojo M; Stewart PM
    J Endocrinol Invest; 1995; 18(7):518-32. PubMed ID: 9221270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroid hormones and hypertension: the cortisol-cortisone shuttle.
    Stewart PM; Whorwood CB; Walker BR
    Steroids; 1993 Dec; 58(12):614-20. PubMed ID: 8116018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 11 beta-Hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
    White PC; Mune T; Rogerson FM; Kayes KM; Agarwal AK
    Pediatr Res; 1997 Jan; 41(1):25-9. PubMed ID: 8979285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of apparent mineralocorticoid excess caused by type 2 11 beta- hydroxysteroid dehydrogenase deficiency].
    Morineau G; Pascoe L; Marc JM; Caillette A; Krozowski Z; Corvol P; Fiet J
    Arch Mal Coeur Vaiss; 1997 Aug; 90(8):1111-5. PubMed ID: 9404418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle.
    Stewart PM; Corrie JE; Shackleton CH; Edwards CR
    J Clin Invest; 1988 Jul; 82(1):340-9. PubMed ID: 3164727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When is cortisol a mineralocorticoid?
    Clore J; Schoolwerth A; Watlington CO
    Kidney Int; 1992 Dec; 42(6):1297-308. PubMed ID: 1474763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does kidney transplantation normalise cortisol metabolism in apparent mineralocorticoid excess syndrome?
    Palermo M; Delitala G; Sorba G; Cossu M; Satta R; Tedde R; Pala A; Shackleton CH
    J Endocrinol Invest; 2000; 23(7):457-62. PubMed ID: 11005270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular analysis of 11 beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
    White PC; Mune T; Rogerson FM; Kayes KM; Agarwal AK
    Steroids; 1997 Jan; 62(1):83-8. PubMed ID: 9029720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apparent mineralocorticoid excess causing hypertension and hypokalemia in children.
    New MI; Stoner E; DiMartino-Nardi J
    Clin Exp Hypertens A; 1986; 8(4-5):751-72. PubMed ID: 3463439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension.
    Ferrari P; Lovati E; Frey FJ
    J Hypertens; 2000 Mar; 18(3):241-8. PubMed ID: 10726708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defects in the HSD11 gene encoding 11 beta-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency.
    Nikkilä H; Tannin GM; New MI; Taylor NF; Kalaitzoglou G; Monder C; White PC
    J Clin Endocrinol Metab; 1993 Sep; 77(3):687-91. PubMed ID: 8370690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cortisol-cortisone shuttle and the apparent specificity of glucocorticoid and mineralocorticoid receptors.
    Edwards CR; Stewart PM
    J Steroid Biochem Mol Biol; 1991 Nov; 39(5B):859-65. PubMed ID: 1659446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apparent mineralocorticoid excess type II.
    Mantero F; Tedde R; Opocher G; Dessi Fulgheri P; Arnaldi G; Ulick S
    Steroids; 1994 Feb; 59(2):80-3. PubMed ID: 8191552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 11beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
    White PC
    Am J Med Sci; 2001 Dec; 322(6):308-15. PubMed ID: 11780688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension.
    Odermatt A; Dick B; Arnold P; Zaehner T; Plueschke V; Deregibus MN; Repetto H; Frey BM; Frey FJ; Ferrari P
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1247-52. PubMed ID: 11238516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organ-specific actions of 11 beta-hydroxysteroid dehydrogenase in humans: implications for the pathophysiology of hypertension.
    Walker BR
    Steroids; 1994 Feb; 59(2):84-9. PubMed ID: 8191553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apparent mineralocorticoid excess.
    Funder JW
    Endocrinol Metab Clin North Am; 1995 Sep; 24(3):613-21. PubMed ID: 8575412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.